サンプルお申込み

お問い合わせ

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は非小細胞肺がんの治療市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートは非小細胞肺がんの治療の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界の非小細胞肺がんの治療市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートは非小細胞肺がんの治療のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別に非小細胞肺がんの治療市場を分類しています。本研究に含まれる主な企業は：GlaxoSmithKline、Novartis、AstraZeneca、Roche、Bristol-Myers Squibb、Pfizer、Eli Lilly、Sanofi

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Alimta
    Iressa
    Avastin
    Tarceva
    Zykadia
    Tagrisso
    Xalkori
    Cyramza
    Opdivo
    Alecensa

用途別の市場セグメント：
    Hospital
    Clinic

本レポートの詳細内容
世界の非小細胞肺がんの治療市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、非小細胞肺がんの治療タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業の非小細胞肺がんの治療収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の非小細胞肺がんの治療市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、非小細胞肺がんの治療市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

非小細胞肺がんの治療のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：非小細胞肺がんの治療のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：非小細胞肺がんの治療の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章非小細胞肺がんの治療企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：非小細胞肺がんの治療の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：非小細胞肺がんの治療の主要企業の概要を提供し、製品の説明と仕様、非小細胞肺がんの治療の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

Market Analysis and Insights: Global Non-small Cell Lung Cancer Therapeutics Market
The global Non-small Cell Lung Cancer Therapeutics market is projected to grow from US$ 9711.3 million in 2024 to US$ 14010 million by 2030, at a Compound Annual Growth Rate (CAGR) of 6.3% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Non-small Cell Lung Cancer Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Non-small Cell Lung Cancer Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Non-small Cell Lung Cancer Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Non-small Cell Lung Cancer Therapeutics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Non-small Cell Lung Cancer Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Non-small Cell Lung Cancer Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GlaxoSmithKline, Novartis, AstraZeneca, Roche, Bristol-Myers Squibb, Pfizer, Eli Lilly and Sanofi, etc.

Market Segmentation
By Company
    GlaxoSmithKline
    Novartis
    AstraZeneca
    Roche
    Bristol-Myers Squibb
    Pfizer
    Eli Lilly
    Sanofi

Segment by Type
    Alimta
    Iressa
    Avastin
    Tarceva
    Zykadia
    Tagrisso
    Xalkori
    Cyramza
    Opdivo
    Alecensa

Segment by Application
    Hospital
    Clinic

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Non-small Cell Lung Cancer Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-small Cell Lung Cancer Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non-small Cell Lung Cancer Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Alimta
    Table 3. Key Players of Iressa
    Table 4. Key Players of Avastin
    Table 5. Key Players of Tarceva
    Table 6. Key Players of Zykadia
    Table 7. Key Players of Tagrisso
    Table 8. Key Players of Xalkori
    Table 9. Key Players of Cyramza
    Table 10. Key Players of Opdivo
    Table 11. Key Players of Alecensa
    Table 12. Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 13. Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 14. Global Non-small Cell Lung Cancer Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 15. Global Non-small Cell Lung Cancer Therapeutics Market Share by Region (2019-2024)
    Table 16. Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 17. Global Non-small Cell Lung Cancer Therapeutics Market Share by Region (2025-2030)
    Table 18. Non-small Cell Lung Cancer Therapeutics Market Trends
    Table 19. Non-small Cell Lung Cancer Therapeutics Market Drivers
    Table 20. Non-small Cell Lung Cancer Therapeutics Market Challenges
    Table 21. Non-small Cell Lung Cancer Therapeutics Market Restraints
    Table 22. Global Non-small Cell Lung Cancer Therapeutics Revenue by Players (2019-2024) & (US$ Million)
    Table 23. Global Non-small Cell Lung Cancer Therapeutics Revenue Share by Players (2019-2024)
    Table 24. Global Top Non-small Cell Lung Cancer Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-small Cell Lung Cancer Therapeutics as of 2023)
    Table 25. Global Non-small Cell Lung Cancer Therapeutics Industry Ranking 2022 VS 2023 VS 2024
    Table 26. Global 5 Largest Players Market Share by Non-small Cell Lung Cancer Therapeutics Revenue (CR5 and HHI) & (2019-2024)
    Table 27. Global Key Players of Non-small Cell Lung Cancer Therapeutics, Headquarters and Area Served
    Table 28. Global Key Players of Non-small Cell Lung Cancer Therapeutics, Product and Application
    Table 29. Global Key Players of Non-small Cell Lung Cancer Therapeutics, Product and Application
    Table 30. Mergers & Acquisitions, Expansion Plans
    Table 31. Global Non-small Cell Lung Cancer Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 32. Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2019-2024)
    Table 33. Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 34. Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2025-2030)
    Table 35. Global Non-small Cell Lung Cancer Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 36. Global Non-small Cell Lung Cancer Therapeutics Revenue Share by Application (2019-2024)
    Table 37. Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 38. Global Non-small Cell Lung Cancer Therapeutics Revenue Share by Application (2025-2030)
    Table 39. North America Non-small Cell Lung Cancer Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 40. North America Non-small Cell Lung Cancer Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 41. North America Non-small Cell Lung Cancer Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 42. North America Non-small Cell Lung Cancer Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 43. North America Non-small Cell Lung Cancer Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 45. North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 46. Europe Non-small Cell Lung Cancer Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 47. Europe Non-small Cell Lung Cancer Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 48. Europe Non-small Cell Lung Cancer Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 49. Europe Non-small Cell Lung Cancer Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 50. Europe Non-small Cell Lung Cancer Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 51. Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 52. Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 53. China Non-small Cell Lung Cancer Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 54. China Non-small Cell Lung Cancer Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 55. China Non-small Cell Lung Cancer Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 56. China Non-small Cell Lung Cancer Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 57. Asia Non-small Cell Lung Cancer Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 58. Asia Non-small Cell Lung Cancer Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 59. Asia Non-small Cell Lung Cancer Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 60. Asia Non-small Cell Lung Cancer Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 61. Asia Non-small Cell Lung Cancer Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 62. Asia Non-small Cell Lung Cancer Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 63. Asia Non-small Cell Lung Cancer Therapeutics Market Size by Region (2025-2030) & (US$ Million)
    Table 64. Middle East, Africa, and Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 65. Middle East, Africa, and Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 66. Middle East, Africa, and Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 67. Middle East, Africa, and Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 68. Middle East, Africa, and Latin America Non-small Cell Lung Cancer Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 69. Middle East, Africa, and Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 70. Middle East, Africa, and Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 71. GlaxoSmithKline Company Details
    Table 72. GlaxoSmithKline Business Overview
    Table 73. GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Product
    Table 74. GlaxoSmithKline Revenue in Non-small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
    Table 75. GlaxoSmithKline Recent Developments
    Table 76. Novartis Company Details
    Table 77. Novartis Business Overview
    Table 78. Novartis Non-small Cell Lung Cancer Therapeutics Product
    Table 79. Novartis Revenue in Non-small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
    Table 80. Novartis Recent Developments
    Table 81. AstraZeneca Company Details
    Table 82. AstraZeneca Business Overview
    Table 83. AstraZeneca Non-small Cell Lung Cancer Therapeutics Product
    Table 84. AstraZeneca Revenue in Non-small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
    Table 85. AstraZeneca Recent Developments
    Table 86. Roche Company Details
    Table 87. Roche Business Overview
    Table 88. Roche Non-small Cell Lung Cancer Therapeutics Product
    Table 89. Roche Revenue in Non-small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
    Table 90. Roche Recent Developments
    Table 91. Bristol-Myers Squibb Company Details
    Table 92. Bristol-Myers Squibb Business Overview
    Table 93. Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Product
    Table 94. Bristol-Myers Squibb Revenue in Non-small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
    Table 95. Bristol-Myers Squibb Recent Developments
    Table 96. Pfizer Company Details
    Table 97. Pfizer Business Overview
    Table 98. Pfizer Non-small Cell Lung Cancer Therapeutics Product
    Table 99. Pfizer Revenue in Non-small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
    Table 100. Pfizer Recent Developments
    Table 101. Eli Lilly Company Details
    Table 102. Eli Lilly Business Overview
    Table 103. Eli Lilly Non-small Cell Lung Cancer Therapeutics Product
    Table 104. Eli Lilly Revenue in Non-small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
    Table 105. Eli Lilly Recent Developments
    Table 106. Sanofi Company Details
    Table 107. Sanofi Business Overview
    Table 108. Sanofi Non-small Cell Lung Cancer Therapeutics Product
    Table 109. Sanofi Revenue in Non-small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
    Table 110. Sanofi Recent Developments
    Table 111. Research Programs/Design for This Report
    Table 112. Key Data Information from Secondary Sources
    Table 113. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Non-small Cell Lung Cancer Therapeutics Market Share by Type: 2023 VS 2030
    Figure 3. Alimta Features
    Figure 4. Iressa Features
    Figure 5. Avastin Features
    Figure 6. Tarceva Features
    Figure 7. Zykadia Features
    Figure 8. Tagrisso Features
    Figure 9. Xalkori Features
    Figure 10. Cyramza Features
    Figure 11. Opdivo Features
    Figure 12. Alecensa Features
    Figure 13. Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 14. Global Non-small Cell Lung Cancer Therapeutics Market Share by Application: 2023 VS 2030
    Figure 15. Hospital Case Studies
    Figure 16. Clinic Case Studies
    Figure 17. Non-small Cell Lung Cancer Therapeutics Report Years Considered
    Figure 18. Global Non-small Cell Lung Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 19. Global Non-small Cell Lung Cancer Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 20. Global Non-small Cell Lung Cancer Therapeutics Market Share by Region: 2023 VS 2030
    Figure 21. Global Non-small Cell Lung Cancer Therapeutics Market Share by Players in 2023
    Figure 22. Global Top Non-small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-small Cell Lung Cancer Therapeutics as of 2023)
    Figure 23. The Top 10 and 5 Players Market Share by Non-small Cell Lung Cancer Therapeutics Revenue in 2023
    Figure 24. North America Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. North America Non-small Cell Lung Cancer Therapeutics Market Share by Type (2019-2030)
    Figure 26. North America Non-small Cell Lung Cancer Therapeutics Market Share by Application (2019-2030)
    Figure 27. North America Non-small Cell Lung Cancer Therapeutics Market Share by Country (2019-2030)
    Figure 28. United States Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Canada Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Europe Non-small Cell Lung Cancer Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 31. Europe Non-small Cell Lung Cancer Therapeutics Market Share by Type (2019-2030)
    Figure 32. Europe Non-small Cell Lung Cancer Therapeutics Market Share by Application (2019-2030)
    Figure 33. Europe Non-small Cell Lung Cancer Therapeutics Market Share by Country (2019-2030)
    Figure 34. Germany Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. France Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. U.K. Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. Italy Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. Russia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 39. Nordic Countries Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 40. China Non-small Cell Lung Cancer Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 41. China Non-small Cell Lung Cancer Therapeutics Market Share by Type (2019-2030)
    Figure 42. China Non-small Cell Lung Cancer Therapeutics Market Share by Application (2019-2030)
    Figure 43. Asia Non-small Cell Lung Cancer Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 44. Asia Non-small Cell Lung Cancer Therapeutics Market Share by Type (2019-2030)
    Figure 45. Asia Non-small Cell Lung Cancer Therapeutics Market Share by Application (2019-2030)
    Figure 46. Asia Non-small Cell Lung Cancer Therapeutics Market Share by Region (2019-2030)
    Figure 47. Japan Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. South Korea Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 49. China Taiwan Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 50. Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 51. India Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Australia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Middle East, Africa, and Latin America Non-small Cell Lung Cancer Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 54. Middle East, Africa, and Latin America Non-small Cell Lung Cancer Therapeutics Market Share by Type (2019-2030)
    Figure 55. Middle East, Africa, and Latin America Non-small Cell Lung Cancer Therapeutics Market Share by Application (2019-2030)
    Figure 56. Middle East, Africa, and Latin America Non-small Cell Lung Cancer Therapeutics Market Share by Country (2019-2030)
    Figure 57. Brazil Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. Mexico Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 59. Turkey Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 60. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 61. Israel Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 62. GCC Countries Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 63. GlaxoSmithKline Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2019-2024)
    Figure 64. Novartis Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2019-2024)
    Figure 65. AstraZeneca Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2019-2024)
    Figure 66. Roche Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2019-2024)
    Figure 67. Bristol-Myers Squibb Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2019-2024)
    Figure 68. Pfizer Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2019-2024)
    Figure 69. Eli Lilly Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2019-2024)
    Figure 70. Sanofi Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2019-2024)
    Figure 71. Bottom-up and Top-down Approaches for This Report
    Figure 72. Data Triangulation
    Figure 73. Key Executives Interviewed